The US Congress has voted to override President George W Bush's veto of the Medicare Improvement for Patients and Providers Act of 2008 (HR 6331) in an unusual move. In order to do this, both the House of Representatives, with 383 votes to 41, and the Senate, 70 to 26, approved the blocked legislation by over two-thirds. A 10.6% cut in physician reimbursements under the Medicare program has now been scrapped, but a year-on-year expansion of end-stage renal disease care has been provided for under the HR 6331 Act.
According to analysts at Lehman Brothers, the switch to a bundled payment system and an annual update on dialysis service reimbursement is likely to benefit the manufacturers of related medical devices. However, Lehman's Ed Ridley-Day also noted that erythropoiesis-stimulating agents such as erythropoietin will be included in the federal program's expansion.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze